Synonyms: AZ 628 | AZ-628
Compound class:
Synthetic organic
Comment: AZ628 is an experimental inhibitor of RAF kinases [1]. Preclinical data for AZ628 was presented at the AACR Annual Meeting by Shen et al. in 2007 (Linking molecular characteristics to the pharmacological response of a panel of cancer cell lines to the BRAF inhibitor, AZ628).
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Mechanism Of Action and Pharmacodynamic Effects |
The Ras/Raf/MEK/ERK pathway has been reported to contribute to the tumourigenic phenotype by inducing immortalisation, growth factor-independent growth, insensitivity to growth-inhibitory signals, ability to invade and metastasis, stimulating angiogenesis and inhibition of apoptosis [2]. The Raf kinases act as proto-oncogenes near the top of this pathway, and are being investigated as molecular targets for pharmacological inhibition in cancer. |